WHAT IS CLAIMED IS:

1. A pharmaceutical carrier comprising an emulsifier.

2. A pharmaceutical carrier according to claim 1 further comprising a polymeric dissolution aid.

3. A pharmaceutical composition comprising a pharmaceutical carrier according to any of claims 1 or 2.

4. A pharmaceutical carrier or composition according to any of claims 1 to 3 wherein said emulsifier is a polyglycolized glyceride.

5. A pharmaceutical carrier or composition according to any of claims 1 to 4 wherein said emulsifier is selected from the group consisting of Labrafil, Labrosol, and Gelucire.

6. A pharmaceutical carrier or composition according to any of claims 1 to 5 wherein said emulsifier is selected from the group consisting of Gelucire 50/13, Gelucire 44/14, and mixtures thereof.

7. A pharmaceutical carrier or composition according to any of claims 1 to 6 wherein said polymeric dissolution aid is selected from the group consisting of polymers of 1-ethenyl-2-pyrrolidinone; polyamine N-oxide polymers; copolymers of N-vinylpyrrolidone and N-vinylimidazole; polyvinyloxazolidones and polyvinylimidazoles or mixtures thereof.

8. A pharmaceutical carrier or composition according to any of claims 1 to 7 wherein said polymeric dissolution aid is a polymer of 1-ethenyl-2-pyrrolidinone.

9. A pharmaceutical carrier or composition according to any of claims 1 to 8 wherein said polymeric dissolution aid is polyvinylpyrrolidone.

10. A pharmaceutical carrier or composition according to any of claims 1 to 9 further comprising a binder, filler, dispersant or wetting agent, disintegrant, or lubricant.

11. A pharmaceutical carrier or composition according to any of claims 1 to 10 further comprising one or more components selected from the group consisting of water, a nonaqueous solvent, a coating, a capsule shell, a colorant, a flavoring, a preservative, an antioxidant, a flavor enhancer, a compression aid, and a surfactant.

12. A pharmaceutical composition according to any of claims 3 to 11 in the form of a tablet.

13. A pharmaceutical composition according to any of claims 3 to 11 in the form of a capsule.




14. A pharmaceutical composition according to any of claims 3 to13 wherein said pharmaceutical active is an antimicrobial agent.



15. A pharmaceutical composition according to any of claims 3 to 14 wherein said antimicrobial agent is selected from the group consisting of oxazolidinones (e.g., linezolid, eperezolid, N-[3-(2-fluoro-4'-{[(3H-[1,2,3]triazol-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide, and other oxazolidinones), macrolides, ketolides, streptogramin As, streptogramin Bs, chloramphenicol and chloramphenicol derivatives, fluorfenicol and fluorfenicol derivatives, glycopeptides, pleuromutilins, aminoglycosides, beta-lactams and carbapenems (including carbapenems with a 7-acylated imidazo[5-1,*b*]thiazole-2-yl group directly attached to the carbapenem moiety of the C-2 position), cephalosporins, lincosamides, quinolones and fluoroquinolones (including pyridonecarboxylic acid derivatives, garenoxacin, gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin) benzoheterocyclic

compounds, aminomethylcycline compounds, dalbavancin, daptomycin, oritavancin, and televancin, or a pharmaceutically acceptable salt, ester, or prodrug thereof, or mixtures thereof.

16. A pharmaceutical composition according to any of claims 3 to 15 wherein said antimicrobial agent is an oxazolidinone.

17. A pharmaceutical composition according to any of claims 3 to 16 wherein said antibiotic compound is selected from the group consisting of

A	
	(5S)-N-(3-{2-Fluoro-4'-[(3-fluoro-propylamino)-methyl]-biphenyl-4-yl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide
B	
	(5S)-N-[3-(2-Fluoro-4'-{[(3-fluoro-propyl)-hydroxy-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide
C	
	N-[3-(2-Fluoro-4'-{[(3H-[1,2,3]triazol-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide

D	
	3-(2-Fluoro-4'-{[(3H-[1,2,3]triazol-4-ylmethyl)-amino]-methyl}-biphenyl-4-yl)-5-(R)-[1,2,3]triazol-1-ylmethyl-oxazolidin-2-one
and E	
	Linezolid or (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl]-acetamide

or a pharmaceutically, acceptable salt, ester or prodrug thereof.

18. A method of treating a microbial infection in a patient comprising administering a pharmaceutically effective amount of a pharmaceutical composition according to any of claims 3 to 17.

19. A method of preventing a microbial infection in a patient comprising administering a prophylactically effective amount of a pharmaceutical composition according to any of claims 3 to 17.

20. A method of reducing the risk of a microbial infection in a patient comprising administering a prophylactically effective amount of a pharmaceutical composition according to any of claims 3 to 17.

21. A pharmaceutical composition for treating a microbial infection in a patient according to any of claims 3 to 17.

22. A pharmaceutical composition for preventing a microbial infection in a patient according to any of claims 3 to 17.

23. A pharmaceutical composition for reducing the risk of a microbial infection in a patient according to any of claims 3 to 17.

24. The use of an antibiotic compound in the manufacture of a pharmaceutical composition according to any of claims 3 to 17 for treating a microbial infection in a patient comprising administering a pharmaceutically effective amount of said pharmaceutical composition to said patient.

25. The use of an antibiotic compound in the manufacture of a pharmaceutical composition according to any of claims 3 to 17 for preventing a microbial infection in a patient comprising administering a prophylactically effective amount of said pharmaceutical composition to said patient.

26. The use of an antibiotic compound in the manufacture of a pharmaceutical composition according to any of claims 3 to 17 for reducing the risk of a microbial infection in a patient comprising administering a prophylactically effective amount of said pharmaceutical composition to said patient.

27. A method, composition, or use according to any of claims 18 to 26 wherein said patient is a mammal or a domestic animal.

28. A method, composition, or use according to any of claims 18-27 wherein said patient is a human.

29. A method, composition, or use according to any of claims 1-28 wherein the composition, compared to a control composition, provides at least a 5 % improvement in dissolution in a two step dissolution testing system.

30. A method, composition, or use according to claim 29 wherein the two step dissolution system comprises measuring the dissolution in a first step in a simulated gastric environment of about pH 4 for up to 30 minutes followed by measuring the dissolution in a second step in a simulated gastric environment of about pH 5.4 to about 6.5 for up to about 60 minutes.

WHAT IS CLAIMED IS:

1. A method of preventing a microbial infection in a patient comprising administering a prophylactically effective amount of a pharmaceutical composition comprising linezolid and a pharmaceutical carrier which comprises an emulsifier and a polymeric dissolution aid.